Antibody–drug conjugate (ADCs), which aim to target highly cytotoxic drugs specifically to cancer cells, are one of the fastest growing classes of anticancer therapeutics, with more than 50 such agents currently in clinical trials. This Review discusses lessons learned and emerging strategies in the development of ADCs, including aspects such as target selection, the development of warheads, the optimization of linkers and new conjugation chemistries, and provides an overview of agents that are currently in clinical trials.

中文翻译：

---

下一代抗体-药物偶联物的策略和挑战。

抗体-药物偶联物（ADC）旨在将高度细胞毒性的药物专门针对癌细胞，是发展最快的一类抗癌药物之一，目前有50多种此类药物正在临床试验中。这篇综述讨论了ADC发展中的经验教训和新兴策略，包括目标选择，弹头的开发，接头的优化和新的结合化学等方面，并概述了目前正在临床试验中的药物。